Bio News
Pfizer’s oral JAK inhibitor Litfulo met the coprimary endpoints in phase 3 trials for nonsegmental vitiligo. The trials included two studies in patients aged 12 years and older and adults, and the Litfulo group showed statistically significant improvements versus placebo at week 52 on F-VASI75 and T-VASI50. Based on these results, Pfizer plans to seek approval for adults from global regulatory agencies and plans to present additional data at a future medical meeting.
BIOBOOK TEAM
biobookmedia@biobook.co.krMinistry of Trade, Industry and Energy and Ministry of Food and Drug Safety Sign Agreement on AI Transformation and Global Competitiveness in Biotech
Paragon Spin-Off Velaris Goes Public Through Reverse Merger With Alaunos
Syndax halts development of Niktimvo for pulmonary fibrosis; shares plunge 17%
BioNTech’s mRNA Cancer Vaccine Misses Primary Endpoint for Progression-Free Survival in Phase 3 Trial
Roche Signs $1.6 Billion Deal With China’s Rona for ALK7 Obesity Drug
Formycon and Zydus’ Keytruda Biosimilar Is First to Be Accepted for FDA Review
